Opioid Abuse Deterrence: Purdue Expects Quick Results On OxyContin, But Cmte. Wonders About Duration Of Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
The surveillance system for tracking adverse events associated with the reformulated drug continues to evolve, the firm tells an FDA advisory panel.
You may also be interested in...
No Abuse-Resistance Claim For Endo’s Opana ER Reformulation
Endo’s Opana ER reformulation, which uses proprietary technology to deter crushing, receives approval but no labeling language on crush-resistance or abuse deterrence, according to FDA. The company says a U.S. patent to be issued Dec. 13 will protect the new formulation until November 2023.
Abuse-Resistant Opioids: How Much Deterrence Is Enough For A Labeling Claim?
FDA advisory committee will consider post-market study plans for King's Embeda and Purdue's reformulated OxyContin.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.